Thus, the combination of HDAC2 inhibitor and PD-1/PD-L1 immunotherapy is hypothesized as a novel tumor treatment strategy with great clinical application and research prospects, which provides a new opportunity to further improve the overall prognosis of patients with HCC [28–31]. The gene discussed is PDCD1; the disease is neoplasm.